This case report describes the clinical balance sheet, which was preceded by a change in therapy of a "typical" 58-year-old patient with metabolic syndrome and poorly controlled diabetes, for whom treatment by GLP-1 receptor agonists was the logical choice for a chance to improve glycemic control.